Montezuma Diana, Malheiros Daniela, Schmitt Fernando C
Portuguese Institute of Oncology, Porto, Portugal.
Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal.
Acta Cytol. 2019 Feb 15:1-6. doi: 10.1159/000492638.
Recently the International Academy of Cytology (IAC) proposed a new reporting system for breast fine needle aspiration biopsy (FNAB) cytology. We aimed to categorize our samples according to this classification and to assess the risk of malignancy (ROM) for each category as well as the diagnostic yield of breast FNAB.
Breast FNAB specimens obtained between January 2007 and December 2017 were reclassified according to the newly proposed IAC Yokohama reporting system. The ROM for each category was determined. Diagnostic yield was evaluated based on a three-category approach, benign versus malignant.
The samples were distributed as follows: insufficient material 5.77%, benign 73.38%, atypical 13.74%, suspicious for malignancy 1.57%, and malignant 5.54%. Of the 3,625 cases collected, 776 (21.4%) had corresponding histology. The respective ROM for each category was 4.8% for category 1 (insufficient material), 1.4% for category 2 (benign), 13% for category 3 (atypical), 97.1% for category 4 (suspicious for malignancy), and 100% for category 5 (malignant). When only malignant cases were considered positive tests, the sensitivity, specificity, and diagnostic accuracy were 97.56, 100, and 99.11%, respectively.
Our study is the first to categorize breast FNAB cytology samples according to the proposed IAC reporting system and to evaluate patient outcomes based on this categorization.
最近,国际细胞学会(IAC)提出了一种新的乳腺细针穿刺活检(FNAB)细胞学报告系统。我们旨在根据这一分类对我们的样本进行分类,并评估每一类别的恶性风险(ROM)以及乳腺FNAB的诊断率。
根据新提出的IAC横滨报告系统,对2007年1月至2017年12月期间获得的乳腺FNAB标本进行重新分类。确定每一类别的ROM。基于良性与恶性的三类方法评估诊断率。
样本分布如下:材料不足5.77%,良性73.38%,非典型13.74%,可疑恶性1.57%,恶性5.54%。在收集的3625例病例中,776例(21.4%)有相应的组织学检查结果。每一类别的ROM分别为:第1类(材料不足)4.8%,第2类(良性)1.4%,第3类(非典型)13%,第4类(可疑恶性)97.1%,第5类(恶性)100%。当仅将恶性病例视为阳性检测时,敏感性、特异性和诊断准确性分别为97.56%、100%和99.11%。
我们的研究首次根据提议的IAC报告系统对乳腺FNAB细胞学样本进行分类,并基于此分类评估患者的预后。